RxDoctor Payments Data

Leah Zambouros, NP

Nurse Practitioner · Asheville, NCNPI 1316558588

Payments from drug & device makers

$7,132in general payments, 2019–2025

Across 270 payments — averaging $26.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Actelion Pharmaceuticals US, Inc.$750
  • Boehringer Ingelheim$699
  • AstraZeneca$335
  • Merck$304
  • Pfizer$296
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$7,123100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,132 in reported general payments places this provider in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$10,354
Medicare patients
71
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan192$233,992
JardianceEmpagliflozin136$135,386
EliquisApixaban83$76,843
FarxigaDapagliflozin Propanediol81$72,391
XareltoRivaroxaban12$10,395
BrilintaTicagrelor12$5,327
Torsemide234$3,617
Metoprolol Succinate179$2,228
Potassium Chloride75$1,387
Dofetilide11$1,237
Spironolactone218$1,039
Eplerenone25$860
Carvedilol121$819
Atorvastatin Calcium113$804
Valsartan44$756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$69$233,992192 claims
Boehringer IngelheimJardiance$699$135,386136 claims
AstraZenecaFarxiga, Brilinta$335$77,71893 claims
PfizerEliquis$296$76,84383 claims
Johnson & JohnsonXarelto$14$10,39512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →